Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization.
Saved in:
| Title: | Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization. |
|---|---|
| Authors: | Martinez, Suky (AUTHOR), Garcia-Romeu, Albert (AUTHOR), Wisdom, Jennifer (AUTHOR), Jones, Jermaine (AUTHOR) |
| Source: | AIDS Care. Apr2026, Vol. 38 Issue 4, p856-869. 14p. |
| Subjects: | HIV infection risk factors, HIV prevention, Risk assessment, Health services accessibility, Methamphetamine, Therapeutics, Qualitative research, Research funding, Pharmaceutical chemistry, Human sexuality, Interviewing, Descriptive statistics, Pre-exposure prophylaxis, Attitude (Psychology), Sex customs, Thematic analysis, Sound recordings, Research methodology, Content mining, Data analysis software, Patients' attitudes |
| Abstract: | Methamphetamine use often co-occurs with sexual behaviors that may increase HIV acquisition risk and disrupt adherence to HIV pre-exposure prophylaxis (PrEP). To explore barriers and opportunities for PrEP among people who use methamphetamine, we conducted semi-structured interviews with 28 self-reported HIV-negative adults (ages 18–55) with current moderate-to-high risk methamphetamine use in the New York City metropolitan area. Transcripts were thematically analyzed with double coding and iterative consensus. Participants described sexualized methamphetamine use, polysubstance use, and sexual behaviors associated with increased HIV exposure risk (condomless intercourse, group sex, transactional sex, encounters with unfamiliar partners). Awareness of PrEP was high (86%), whereas 46% reported current use. Adherence frequently decreased during periods of heavy methamphetamine and polysubstance use, despite self-management strategies (e.g., phone/calendar reminders). Reported obstacles included insurance coverage interruptions, concerns about side effects, and reluctance to discuss sexual health with clinicians. Interest in long-acting PrEP was considerable (71% would try injections; 57% would try implants), though some expressed concerns about comparative efficacy, visit adherence, and access. Findings suggest that long-acting formulations may mitigate daily dosing burdens, particularly if delivered in settings already accessed by this population. Prospective clinical studies, ideally randomized trials, are needed to determine whether long-acting PrEP improves adherence and reduces HIV incidence in methamphetamine-using populations. Trial registration: ClinicalTrials.gov identifier: NCT06101342. [ABSTRACT FROM AUTHOR] |
| Copyright of AIDS Care is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
Be the first to leave a comment!
